Cogent Biosciences, Inc.
COGT
Rank in Stocks
#3336
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Share Price
$30.11
Last synced: 2026-10-19
Market Cap
$5.22B
Change (1 day)
2.00%
Change (1 year)
85.64%
Country
US
Trade Cogent Biosciences, Inc. (COGT)
Category
Healthcare
P/S ratio for Cogent Biosciences, Inc. (COGT)
P/S ratio as of October 2026 TTM: 0.00
According to Cogent Biosciences, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 0.00.
P/S ratio history for Cogent Biosciences, Inc. from 2015 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | 15.81 | 1,520.90% |
| 2019 | 0.98 | -91.33% |
| 2018 | 11.25 | -71.38% |
| 2017 | 39.32 | -3.98% |
| 2016 | 40.95 | -53.01% |
| 2015 | 87.14 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
